Market Overview

UPDATE: Credit Suisse Initiates Immunogen at Neutral on Valuation

Share:
Related IMGN
4 After-Hours Movers: Earnings, Strategic Reviews & Offerings Shaking Stocks
Jefferies Sees Risks From Lack Of Data Supporting ImmunoGen Drug Trial, Cuts Price Target In Half

Credit Suisse initiated coverage on Immunogen (NASDAQ: IMGN) with a Neutral rating and a $12 price target.

Credit Suisse noted, "We like IMGN for its expected steady cash flow from T-DM1 royalties, its antibody-drug conjugation (ADC) technology, and potential upside from a deep pipeline. However, upside to valuation requires additional drivers for which visibility is currently low."

Immunogen closed at $11.65 on Monday.

Latest Ratings for IMGN

DateFirmActionFromTo
Aug 2016JefferiesMaintainsBuy
Aug 2016JP MorganMaintainsNeutral
May 2016RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (IMGN)

View Comments and Join the Discussion!